Clinical Trials
10 trialsNCT01434316 2026-04-13
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03484520 2022-12-30
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Terminated
NCT01676753 2022-09-21
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02684617 2021-03-01
KEYNOTE-155
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01711528 2018-05-11
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01624441 2018-03-30
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00871910 2017-10-23
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01783171 2017-08-22
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00871663 2015-04-20
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01650727 2015-02-10
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Merck Sharp & Dohme LLC
Phase 1 Completed